Jackpot for Melanoma Patients: Revolutionary Treatment Now Covered by NHS
In a landmark decision, England’s National Health Service (NHS) has announced its coverage of KIMMTRAK, a groundbreaking immunotherapy for rare and aggressive uveal melanoma. The treatment, initially considered too expensive by NICE (National Institute for Health and Care Excellence), becomes accessible to eligible patients nationwide, prompting celebratory responses from both clinicians and patient advocacy groups.
“This is incredible news for patients and their families faced with this devastating disease,” said Professor Paul Nathan, a consultant medical oncologist at Mount Vernon Cancer Centre. "Having KIMMTRAK available on the NHS marks a significant turning point in our ability to fight uveal melanoma — it offers the first real hope for prolonged survival."
Uveal melanoma, a rare cancer affecting the eye, carries a bleak prognosis if it spreads beyond the eye. This news brings reassurance to patients astonished by the initial Nice rejection of the treatment back in May 2023. Following a successful appeal by Immunocore, the company behind KIMMTRAK, NICE reversed its decision, recognizing the drug’s potential to extend lives.
Susanna Daniels, CEO of Melanoma Focus, echoed the positive sentiment: "Today we celebrate a major victory for the uveal melanoma community. The availability of KIMMTRAK through the NHS is a game-changer. It offers a real chance for patients to fight back against this aggressive disease.”
KIMMTRAK marks a paradigm shift in uveal melanoma treatment. This unique immunotherapy utilizes a cutting-edge technology called ImmTAC, harnessing the power of the patient’s own immune system to specifically target and eradicate cancerous cells. This targeted approach promises fewer side effects compared to traditional chemotherapy.
KIMMTRAK (tebentafusp) becomes available through the NHS starting December 2, 2024.
“This is a momentous occasion for all involved,” added Desprez. "We are deeply committed to making KIMMTRAK accessible to every eligible patient across the UK”
